针对人乳头瘤病毒18、45和59型的三价嵌合疫苗的表征
研究开发靶向HPV18/45/59的嵌合病毒样颗粒(VLP)疫苗候选,通过交换HPV18与HPV45及引入HPV59表面环构建H18-45BCEF-59HI。该候选在粒径、形态和热稳定性上与野生型相似,小鼠免疫显示H18-45EF-59HI诱导最优交叉中和,拟在类GMP设施生产。
要点
- 构建H18-45BCEF-59HI嵌合VLP,粒径形态热稳定性类似野生型。
- 小鼠免疫中H18-45EF-59HI嵌合VLP显示最优交叉中和。
- H18-45BCEF-59HI在类GMP设施生产,选为HPV18/45/59感染预防候选。
核心结论
- H18-45BCEF-59HI嵌合VLP被选为预防HPV18/45/59感染的候选疫苗,为当前疫苗未覆盖的HPV59相关癌症提供潜在解决方案。
研究设计与样本
- 研究设计为疫苗候选构建与表征,包括嵌合VLP的工程化、物理化学表征及小鼠免疫原性评估。
主要发现
- H18-45BCEF-59HI在粒径和形态上与野生型骨架类型相似,经透射电镜、高效体积排阻色谱和分析超速离心验证。
- H18-45BCEF-59HI表现出与野生型相似的热稳定性,经差示扫描量热法验证。
- 小鼠免疫研究中,H18-45EF-59HI嵌合VLP表现出最优的交叉中和。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Persistent infection with high-risk human papillomavirus (HPV) types can lead to the development of cancer in HPV-infected tissues, including the cervix, oropharynx, anus, penis, vagina, and vulva. While current HPV vaccines cover approximately 90 % of cervical cancers, nearly 10 % of cases associated with HPV types not included in the vaccines remain unaddressed, notably HPV59. This study describes the development of a chimeric virus-like particle (VLP) targeting HPV18/45/59, proposed as a vaccine candidate for high-risk HPV type (HPV59) currently lacking commercial vaccines. Given that the majority of neutralizing antibody epitopes are located on the surface loops, we engineered a strategic swap of these loops between the closely related HPV18 and HPV45. This methodology was then extended to incorporate surface loops of HPV59, resulting in the lead candidate construct of the H18-45BCEF-59HI chimeric VLP with two surface loops swapping from HPV45 to HPV18. Characterization confirmed that H18-45BCEF-59HI closely resembled the wild-type (WT) backbone types in particle size and morphology, as verified by Transmission Electron Microscopy (TEM), High-Performance Size-Exclusion Chromatography (HPSEC), and Analytical Ultracentrifugation (AUC), and demonstrated similar thermal stability as evidenced by Differential Scanning Calorimetry (DSC). Immunization studies in mice with the chimeric VLPs assessed their immunogenicity, revealing that the H18-45EF-59HI chimeric VLP exhibited optimal cross-neutralization. Additionally, when produced in a Good Manufacturing Practice (GMP)-like facility, the H18-45BCEF-59HI VLP was selected as a promising vaccine candidate for the prevention of HPV18/45/59 infection. This study not only offers a potential solution to the current vaccination gap but also provides a foundational approach for the design of vaccines targeting viruses with multiple subtypes or variants.
引用
- Chi X, Han F, Jiang Y, et al. Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59. Vaccine. 2024. PMID: 39216181. doi:10.1016/j.vaccine.2024.126245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。